Addressing Challenges in Diagnosis and Treatment of Low-Grade Upper Tract Urothelial Carcinoma

To participate in this activity, please:

Upper tract urothelial carcinoma (UTUC) has many similarities to bladder carcinoma, but also some important differences. Join Dr. Seth Lerner, as he contrasts these 2 diseases, as well as important differences between low-grade and high-grade UTUC. Dr. Lerner highlights important considerations in the instruments, imaging, and biopsy techniques for diagnosing low-grade UTUC. Surgical options are considered, with a focus on patient selection for endoscopic nephron-sparing surgery. The safety and efficacy of intracavitary therapy are discussed, with an emphasis on mitomycin for pyelocalyceal solution.

Course Credit:

0.75 AMA PRA Category 1 CreditsTM
0.75 ANCC Contact Hours
0.75 CA-BRN Contact Hours
0.25 Pharmacology Hours

Dates:

Opens: 2021-08-20
Closes: 2022-08-20

Target Audience:

This activity was developed for urologists, oncologists, advanced practitioners, oncology nurses, and other healthcare providers involved in the care of patients with low-grade upper tract urothelial carcinoma.

This educational activity is supported by an educational grant from UroGen.

    Presenting Faculty

  • Seth Lerner, MD

    Professor, Urology
    Beth and Dave Swalm Chair in Urologic Oncology
    Director of Urologic Oncology
    Director of the Multidisciplinary Bladder Cancer Program
    Baylor College of Medicine Medical Center
    Houston, Texas

Learning Objectives

  • Identify techniques to directly view and biopsy malignant abnormalities in the upper urinary tract
  • Distinguish between low- and high-risk UTUC according to the latest guidelines
  • Employ kidney-sparing endoscopic options in treating patients with low-risk, LG-UTUC
  • Describe the safety, efficacy, and patient benefits of mitomycin for pyelocalyceal solution as therapy for LG-UTUC patients in whom tumor ablation with surgery is not feasible
  • Employ upper tract imaging, ureteroscopy, and urine biomarkers to monitor patients for recurrent disease after kidney-sparing treatment for UTUC

Faculty Disclosures

Seth Lerner, MD

Advisory Board: Aura Bioscience, BMS, C2i Genomics, EMD Serono, FerGene, Genentech, Pfizer, QED Therapeutics, UroGen, Vaxiion, Verity

Consultant: Aura Bioscience, BMS, C2i Genomics, EMD Serono, FerGene, Genentech, Pfizer, QED Therapeutics, UroGen, Vaxiion, Verity

Clinical Trials: Endo, FKD, JBL (SWOG), Genentech (SWOG), QED Therapeutics, UroGen, Vaxiion, Viventia

Patent: TCGA classifier

Speakers Bureau: Grand Rounds Urology, Ology, UroToday


Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 0.75 contact hours, including 0.25 pharmacology hours, may be earned for successful completion of this activity.
Provider is approved by the California Board of Registered Nursing, Provider #13664, for 0.75 contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Additional Content Planners

Heather M. Jimenez, FNP-C (Nurse Reviewer)
No significant relationships to disclose.

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.